The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
23
12
2020
accepted:
05
03
2021
revised:
13
02
2021
pubmed:
10
4
2021
medline:
3
3
2022
entrez:
9
4
2021
Statut:
ppublish
Résumé
Matrix metalloproteinases 9 (MMP9) are enzymes involved in regulating neuroplasticity in the hippocampus. This, combined with evidence for disrupted hippocampal structure and function in schizophrenia, has prompted our current investigation into the relationship between MMP9 and hippocampal volumes in schizophrenia. 34 healthy individuals (mean age = 32.50, male = 21, female = 13) and 30 subjects with schizophrenia (mean age = 33.07, male = 19, female = 11) underwent a blood draw and T1-weighted magnetic resonance imaging. The hippocampus was automatically segmented utilizing FreeSurfer. MMP9 plasma levels were measured with ELISA. ANCOVAs were conducted to compare MMP9 plasma levels (corrected for age and sex) and hippocampal volumes between groups (corrected for age, sex, total intracranial volume). Spearman correlations were utilized to investigate the relationship between symptoms, medication, duration of illness, number of episodes, and MMP9 plasma levels in patients. Last, we explored the correlation between MMP9 levels and hippocampal volumes in patients and healthy individuals separately. Patients displayed higher MMP9 plasma levels than healthy individuals (F(1, 60) = 21.19, p < 0.0001). MMP9 levels correlated with negative symptoms in patients (R = 0.39, p = 0.035), but not with medication, duration of illness, or the number of episodes. Further, patients had smaller left (F(1,59) = 9.12, p = 0.0040) and right (F(1,59) = 6.49, p = 0.013) hippocampal volumes. Finally, left (R = -0.39, p = 0.034) and right (R = -0.37, p = 0.046) hippocampal volumes correlated negatively with MMP9 plasma levels in patients. We observe higher MMP9 plasma levels in SCZ, associated with lower hippocampal volumes, suggesting involvement of MMP9 in the pathology of SCZ. Future studies are needed to investigate how MMP9 influences the pathology of SCZ over the lifespan, whether the observed associations are specific for schizophrenia, and if a therapeutic modulation of MMP9 promotes neuroprotective effects in SCZ.
Identifiants
pubmed: 33833403
doi: 10.1038/s41386-021-00997-5
pii: 10.1038/s41386-021-00997-5
pmc: PMC8674225
doi:
Substances chimiques
MMP9 protein, human
EC 3.4.24.35
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
524-530Subventions
Organisme : NIMH NIH HHS
ID : K24 MH110807
Pays : United States
Organisme : NIBIB NIH HHS
ID : P41 EB015902
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
Références
De Picker LJ, Morrens M, Chance SA, Boche D. Microglia and brain plasticity in acute psychosis and schizophrenia illness course: a meta-review. Front Psychiatry. 2017;8:238.
pubmed: 29201010
pmcid: 5696326
doi: 10.3389/fpsyt.2017.00238
Oberman L, Pascual-Leone A. Changes in plasticity across the lifespan: cause of disease and target for intervention. Prog Brain Res. 2013;207:91–120.
pubmed: 24309252
pmcid: 4392917
doi: 10.1016/B978-0-444-63327-9.00016-3
Bernardinelli Y, Nikonenko I, Muller D. Structural plasticity: mechanisms and contribution to developmental psychiatric disorders. Front Neuroanat. 2014;8:123.
pubmed: 25404897
pmcid: 4217507
doi: 10.3389/fnana.2014.00123
McCullumsmith RE, Clinton SM, Meador-Woodruff JH. Schizophrenia as a disorder of neuroplasticity. Int Rev Neurobiol. 2004;59:19–45.
pubmed: 15006483
doi: 10.1016/S0074-7742(04)59002-5
Crabtree GW, Gogos JA. Synaptic plasticity, neural circuits, and the emerging role of altered short-term information processing in schizophrenia. Front Synaptic Neurosci. 2014;6:28.
pubmed: 25505409
pmcid: 4243504
doi: 10.3389/fnsyn.2014.00028
Rybakowski JK. Matrix metalloproteinase-9 (MMP9)-a mediating enzyme in cardiovascular disease, cancer, and neuropsychiatric disorders. Cardiovasc Psychiatry Neurol. 2009;2009:904836.
pubmed: 20037727
pmcid: 2796208
doi: 10.1155/2009/904836
Vafadari B, Salamian A, Kaczmarek L. MMP-9 in translation: from molecule to brain physiology, pathology, and therapy. J Neurochem. 2016;139:91–114.
pubmed: 26525923
doi: 10.1111/jnc.13415
Sathyanesan M, Girgenti MJ, Banasr M, Stone K, Bruce C, Guilchicek E, et al. A molecular characterization of the choroid plexus and stress-induced gene regulation. Transl Psychiatry. 2012;2:e139.
pubmed: 22781172
pmcid: 3410626
doi: 10.1038/tp.2012.64
Dziembowska M, Wlodarczyk J. MMP9: a novel function in synaptic plasticity. Int J Biochem cell Biol. 2012;44:709–13.
pubmed: 22326910
doi: 10.1016/j.biocel.2012.01.023
Bronisz E, Kurkowska-Jastrzębska I. Matrix metalloproteinase 9 in epilepsy: the role of neuroinflammation in seizure development. Mediators Inflamm. 2016;2016:7369020.
pubmed: 28104930
pmcid: 5220508
doi: 10.1155/2016/7369020
Murase S, McKay RD. Matrix metalloproteinase-9 regulates survival of neurons in newborn hippocampus. J Biol Chem. 2012;287:12184–94.
pubmed: 22351756
pmcid: 3320970
doi: 10.1074/jbc.M111.297671
Sidhu H, Dansie LE, Hickmott PW, Ethell DW, Ethell IM. Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. J Neurosci. 2014;34:9867–79.
pubmed: 25057190
pmcid: 4107404
doi: 10.1523/JNEUROSCI.1162-14.2014
Aujla PK, Huntley GW. Early postnatal expression and localization of matrix metalloproteinases-2 and -9 during establishment of rat hippocampal synaptic circuitry. J Comp Neurol. 2014;522:1249–63.
pubmed: 24114974
pmcid: 4909053
doi: 10.1002/cne.23468
Fragkouli A, Papatheodoropoulos C, Georgopoulos S, Stamatakis A, Stylianopoulou F, Tsilibary EC, et al. Enhanced neuronal plasticity and elevated endogenous sAPPalpha levels in mice over-expressing MMP9. J Neurochem. 2012;121:239–51.
pubmed: 22192143
doi: 10.1111/j.1471-4159.2011.07637.x
Gkogkas CG, Khoutorsky A, Cao R, Jafarnejad SM, Prager-Khoutorsky M, Giannakas N, et al. Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes. Cell Rep. 2014;9:1742–55.
pubmed: 25466251
pmcid: 4294557
doi: 10.1016/j.celrep.2014.10.064
Wojcik-Stanaszek L, Gregor A, Zalewska T. Regulation of neurogenesis by extracellular matrix and integrins. Acta Neurobiol. Exp. 2011;71:103–12.
Tsilibary E, Tzinia A, Radenovic L, Stamenkovic V, Lebitko T, Mucha M, et al. Neural ECM proteases in learning and synaptic plasticity. Prog Brain Res. 2014;214:135–57.
pubmed: 25410356
doi: 10.1016/B978-0-444-63486-3.00006-2
Wiera G, Nowak D, van Hove I, Dziegiel P, Moons L, Mozrzymas JW. Mechanisms of NMDA receptor- and voltage-gated L-type calcium channel-dependent hippocampal LTP critically rely on proteolysis that is mediated by distinct metalloproteinases. J Neurosci. 2017;37:1240–56.
pubmed: 28069922
pmcid: 6596865
doi: 10.1523/JNEUROSCI.2170-16.2016
Wiera G, Wozniak G, Bajor M, Kaczmarek L, Mozrzymas JW. Maintenance of long-term potentiation in hippocampal mossy fiber-CA3 pathway requires fine-tuned MMP-9 proteolytic activity. Hippocampus. 2013;23:529–43.
pubmed: 23418057
doi: 10.1002/hipo.22112
Salavati B, Rajji TK, Price R, Sun Y, Graff-Guerrero A, Daskalakis ZJ. Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophr Bull. 2015;41:44–56.
pubmed: 25249654
doi: 10.1093/schbul/sbu132
Meighan SE, Meighan PC, Choudhury P, Davis CJ, Olson ML, Zornes PA, et al. Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J Neurochem. 2006;96:1227–41.
pubmed: 16464240
doi: 10.1111/j.1471-4159.2005.03565.x
Wiera G, Szczot M, Wojtowicz T, Lebida K, Koza P, Mozrzymas JW. Impact of matrix metalloproteinase-9 overexpression on synaptic excitatory transmission and its plasticity in rat CA3-CA1 hippocampal pathway. J Physiol Pharmacol. 2015;66:309–15.
pubmed: 25903961
Bitanihirwe BKY, Woo TW. A conceptualized model linking matrix metalloproteinase-9 to schizophrenia pathogenesis. Schizophr Res. 2020;218:28–35.
pubmed: 32001079
doi: 10.1016/j.schres.2019.12.015
Yamamori H, Hashimoto R, Ishima T, Kishi F, Yasuda Y, Ohi K, et al. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett. 2013;556:37–41.
pubmed: 24141084
doi: 10.1016/j.neulet.2013.09.059
Ali FT, Abd El-Azeem EM, Hamed MA, Ali MAM, Abd Al-Kader NM, Hassan EA. Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: Pathophysiological and phenotypic implications. Schizophr Res. 2017;188:98–109.
pubmed: 28100419
doi: 10.1016/j.schres.2017.01.016
Kumarasinghe N, Beveridge NJ, Gardiner E, Scott RJ, Yasawardene S, Perera A, et al. Gene expression profiling in treatment-naive schizophrenia patients identifies abnormalities in biological pathways involving AKT1 that are corrected by antipsychotic medication. Int J Neuropsychopharmacol. 2013;16:1483–503.
pubmed: 23442539
doi: 10.1017/S1461145713000035
Solmi M, Veronese N, Thapa N, Facchini S, Stubbs B, Fornaro M, et al. Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectr. 2017;22:415–26.
pubmed: 28181901
doi: 10.1017/S1092852916000638
Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012;26:1185–93.
pubmed: 22526685
doi: 10.1177/0269881112444941
Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71:138–49.
pubmed: 19895780
doi: 10.4088/JCP.08m04666yel
Walker MA, Highley JR, Esiri MM, McDonald B, Roberts HC, Evans SP, et al. Estimated neuronal populations and volumes of the hippocampus and its subfields in schizophrenia. Am J Psychiatry. 2002;159:821–8.
pubmed: 11986137
doi: 10.1176/appi.ajp.159.5.821
Highley JR, Walker MA, McDonald B, Crow TJ, Esiri MM. Size of hippocampal pyramidal neurons in schizophrenia. Br J Psychiatry. 2003;183:414–7.
pubmed: 14594916
doi: 10.1192/bjp.183.5.414
Zaidel DW, Esiri MM, Harrison PJ. Size, shape, and orientation of neurons in the left and right hippocampus: investigation of normal asymmetries and alterations in schizophrenia. Am J Psychiatry. 1997;154:812–8.
pubmed: 9167509
doi: 10.1176/ajp.154.6.812
Haukvik UK, Tamnes CK, Soderman E, Agartz I. Neuroimaging hippocampal subfields in schizophrenia and bipolar disorder: a systematic review and meta-analysis. J Psychiatr Res. 2018;104:217–26.
pubmed: 30107268
doi: 10.1016/j.jpsychires.2018.08.012
First MB. Structured Clinical Interview for the DSM (SCID). The Encyclopedia of Clinical Psychology. Hoboken, NJ, USA: John Wiley & Sons; 2015. p. 1-6.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.
pubmed: 3616518
doi: 10.1093/schbul/13.2.261
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:34–57. 22-33;quiz
Chang SH, Chiang SY, Chiu CC, Tsai CC, Tsai HH, Huang CY, et al. Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia. Psychiatry Res. 2011;187:341–6.
pubmed: 20510460
doi: 10.1016/j.psychres.2010.04.049
Gao J, Yi H, Tang X, Feng X, Yu M, Sha W, et al. DNA methylation and gene expression of matrix metalloproteinase 9 gene in deficit and non-deficit schizophrenia. Front Genet. 2018;9:646.
pubmed: 30619470
pmcid: 6297256
doi: 10.3389/fgene.2018.00646
Dwir D, Giangreco B, Xin L, Tenenbaum L, Cabungcal JH, Steullet P, et al. MMP9/RAGE pathway overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory/excitatory imbalance: a reverse translation study in schizophrenia patients. Mol Psychiatry. 2020;25:2889–904.
Mitelman SA, Newmark RE, Torosjan Y, Chu KW, Brickman AM, Haznedar MM, et al. White matter fractional anisotropy and outcome in schizophrenia. Schizophr Res. 2006;87:138–59.
pubmed: 16854563
doi: 10.1016/j.schres.2006.06.016
Bucci P, Mucci A, Piegari G, Nobile M, Pini S, Rossi A, et al. Characterization of premorbid functioning during childhood in patients with deficit vs. non-deficit schizophrenia and in their healthy siblings. Schizophr Res. 2016;174:172–76.
pubmed: 26825584
doi: 10.1016/j.schres.2016.01.032
Gao J, Tang X, Kang J, Xie C, Yu M, Sha W, et al. Correlation between neurocognitive impairment and DNA methylation of MMP-9 gene in patients with deficit schizophrenia. Schizophr Res. 2019;204:455–57.
pubmed: 30337154
doi: 10.1016/j.schres.2018.10.005
Baglivo V, Cao B, Mwangi B, Bellani M, Perlini C, Lasalvia A, et al. Hippocampal subfield volumes in patients with first-episode psychosis. Schizophr Bull. 2018;44:552–59.
pubmed: 29897598
doi: 10.1093/schbul/sbx108
Law AJ, Weickert CS, Hyde TM, Kleinman JE, Harrison PJ. Reduced spinophilin but not microtubule-associated protein 2 expression in the hippocampal formation in schizophrenia and mood disorders: molecular evidence for a pathology of dendritic spines. Am J Psychiatry. 2004;161:1848–55.
pubmed: 15465982
doi: 10.1176/ajp.161.10.1848
Barbeau D, Liang JJ, Robitalille Y, Quirion R, Srivastava LK. Decreased expression of the embryonic form of the neural cell adhesion molecule in schizophrenic brains. Proc Natl Acad Sci USA. 1995;92:2785–9.
pubmed: 7708724
pmcid: 42303
doi: 10.1073/pnas.92.7.2785
Francis AN, Seidman LJ, Tandon N, Shenton ME, Thermenos HW, Mesholam-Gately RI, et al. Reduced subicular subdivisions of the hippocampal formation and verbal declarative memory impairments in young relatives at risk for schizophrenia. Schizophr Res. 2013;151:154–7.
pubmed: 24144441
doi: 10.1016/j.schres.2013.10.002
Haukvik UK, Westlye LT, Morch-Johnsen L, Jorgensen KN, Lange EH, Dale AM, et al. In vivo hippocampal subfield volumes in schizophrenia and bipolar disorder. Biol Psychiatry. 2015;77:581–8.
pubmed: 25127742
doi: 10.1016/j.biopsych.2014.06.020
Niculescu D, Michaelsen-Preusse K, Guner U, van Dorland R, Wierenga CJ, Lohmann C. A BDNF-mediated push-pull plasticity mechanism for synaptic clustering. Cell Rep. 2018;24:2063–74.
pubmed: 30134168
doi: 10.1016/j.celrep.2018.07.073
Jasinska M, Milek J, Cymerman IA, Leski S, Kaczmarek L, Dziembowska M. miR-132 regulates dendritic spine structure by direct targeting of matrix metalloproteinase 9 mRNA. Mol Neurobiol 2016;53:4701–12.
pubmed: 26319558
doi: 10.1007/s12035-015-9383-z
Kondratiuk I, Leski S, Urbanska M, Biecek P, Devijver H, Lechat B, et al. GSK-3beta and MMP-9 cooperate in the control of dendritic spine morphology. Mol Neurobiol. 2017;54:200–11.
pubmed: 26738851
doi: 10.1007/s12035-015-9625-0
Ganguly K, Rejmak E, Mikosz M, Nikolaev E, Knapska E, Kaczmarek L. Matrix metalloproteinase (MMP) 9 transcription in mouse brain induced by fear learning. J Biol Chem. 2013;288:20978–91.
pubmed: 23720741
pmcid: 3774367
doi: 10.1074/jbc.M113.457903
van der Kooij MA, Fantin M, Rejmak E, Grosse J, Zanoletti O, Fournier C, et al. Role for MMP-9 in stress-induced downregulation of nectin-3 in hippocampal CA1 and associated behavioural alterations. Nat Commun. 2014;5:4995.
pubmed: 25232752
doi: 10.1038/ncomms5995
Beroun A, Mitra S, Michaluk P, Pijet B, Stefaniuk M, Kaczmarek L. MMPs in learning and memory and neuropsychiatric disorders. Cell Mol life Sci. 2019;76:3207–28.
pubmed: 31172215
pmcid: 6647627
doi: 10.1007/s00018-019-03180-8
Lepeta K, Kaczmarek L. Matrix metalloproteinase-9 as a novel player in synaptic plasticity and schizophrenia. Schizophr Bull. 2015;41:1003–9.
pubmed: 25837304
pmcid: 4535641
doi: 10.1093/schbul/sbv036
Cho KO, Kim SK, Cho YJ, Sung KW, Kim SY. Regional differences in the neuroprotective effect of minocycline in a mouse model of global forebrain ischemia. Life Sci. 2007;80:2030–5.
pubmed: 17408699
doi: 10.1016/j.lfs.2007.03.005
Lee JH, Lee SR. The effect of Baicalein on hippocampal neuronal damage and metalloproteinase activity following transient global cerebral ischaemia. Phytother Res 2012;26:1614–9.
pubmed: 22344890
doi: 10.1002/ptr.4644
Strzelecki D, Kaluzynska O, Szyburska J, Wysokinski A. MMP-9 serum levels in schizophrenic patients during treatment augmentation with sarcosine (Results of the PULSAR Study). Int J Mol Sci. 2016;17:1075.
Romero JR, Vasan RS, Beiser AS, Au R, Benjamin EJ, DeCarli C, et al. Association of matrix metalloproteinases with MRI indices of brain ischemia and aging. Neurobiol Aging. 2010;31:2128–35.
pubmed: 19128858
doi: 10.1016/j.neurobiolaging.2008.11.004
Rai AL, Jeswar U. Immunohistochemical colocalization of estrogen receptor-alpha and GABA in adult female rat hippocampus. Ann Neurosci. 2012;19:112–5.
pubmed: 25205981
pmcid: 4117079
Corvino V, Di Maria V, Marchese E, Lattanzi W, Biamonte F, Michetti F, et al. Estrogen administration modulates hippocampal GABAergic subpopulations in the hippocampus of trimethyltin-treated rats. Front Cell Neurosci. 2015;9:433.
pubmed: 26594149
pmcid: 4633568
doi: 10.3389/fncel.2015.00433
Niitsu T, Ishima T, Yoshida T, Hashimoto T, Matsuzawa D, Shirayama Y, et al. A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia. Psychiatry Res. 2014;215:268–73.
pubmed: 24377440
doi: 10.1016/j.psychres.2013.12.009
Shu H, Zheng GQ, Wang X, Sun Y, Liu Y, Weaver JM, et al. Activation of matrix metalloproteinase in dorsal hippocampus drives improvement in spatial working memory after intra-VTA nicotine infusion in rats. J Neurochem. 2015;135:357–67.
pubmed: 26263395
doi: 10.1111/jnc.13283
Yin L, Li F, Li J, Yang X, Xie X, Xue L, et al. Chronic intermittent ethanol exposure induces upregulation of matrix metalloproteinase-9 in the rat medial prefrontal cortex and hippocampus. Neurochem Res. 2019;44:1593–601.
pubmed: 30915602
doi: 10.1007/s11064-019-02783-8
Arabska J, Margulska A, Strzelecki D, Wysokinski A. Does metabolic status affect serum levels of BDNF and MMP-9 in patients with schizophrenia? Nord J Psychiatry. 2019:73:515–21.
Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown A, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One. 2010;5:e9166.
pubmed: 20161799
pmcid: 2820097
doi: 10.1371/journal.pone.0009166
Rybakowski JK, Remlinger-Molenda A, Czech-Kucharska A, Wojcicka M, Michalak M, Losy J. Increased serum matrix metalloproteinase-9 (MMP-9) levels in young patients during bipolar depression. J Affect Disord. 2013;146:286–9.
pubmed: 22858217
doi: 10.1016/j.jad.2012.07.019
Fiorentino M, Sapone A, Senger S, Camhi SS, Kadzielski SM, Buie TM, et al. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol Autism. 2016;7:49.
pubmed: 27957319
pmcid: 5129651
doi: 10.1186/s13229-016-0110-z
Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology. 1999;53:1397–401.
pubmed: 10534241
doi: 10.1212/WNL.53.7.1397
Avolio C, Filippi M, Tortorella C, Rocca MA, Ruggieri M, Agosta F, et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler. 2005;11:441–6.
pubmed: 16042227
doi: 10.1191/1352458505ms1193oa
Montaner J, Rovira A, Molina CA, Arenillas JF, Ribo M, Chacon P, et al. Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J Cereb Blood Flow Metab. 2003;23:1403–7.
pubmed: 14663335
doi: 10.1097/01.WCB.0000100044.07481.97
Barr TL, Latour LL, Lee KY, Schaewe TJ, Luby M, Chang GS, et al. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke. 2010;41:e123–8.
pubmed: 20035078
doi: 10.1161/STROKEAHA.109.570515
Fainardi E, Castellazzi M, Bellini T, Manfrinato MC, Baldi E, Casetta I, et al. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult Scler. 2006;12:294–301.
pubmed: 16764342
doi: 10.1191/135248506ms1274oa
Alaiyed S, Bozzelli PL, Caccavano A, Wu JY, Conant K. Venlafaxine stimulates PNN proteolysis and MMP-9-dependent enhancement of gamma power; relevance to antidepressant efficacy. J Neurochem. 2019;148:810–21.
pubmed: 30697747
pmcid: 6516074
doi: 10.1111/jnc.14671
Kay SR, Fizbin A, Lindenmayer JP, Opler LA. Positive and negative syndromes in schizophrenia as a function of chronicity. Acta Psychiatr Scand. 1986;74:507–18.
pubmed: 3492863
doi: 10.1111/j.1600-0447.1986.tb06276.x